MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-06-2026
Canopy Growth Corporation EBITDA per Share 2011-2026 | CGC
Annual EBITDA per Share Canopy Growth Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.89 | -2.68 | -55.5 | -24.1 | -3.15 | - | - | - | - | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.89 | -55.5 | -17.3 |
Quarterly EBITDA per Share Canopy Growth Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.38 | -1.27 | -0.94 | - | -1.48 | -1.34 | -0.67 | - | -0.55 | -0.78 | -0.58 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.38 | -1.48 | -0.888 |
EBITDA per Share of other stocks in the Drug manufacturers industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cumberland Pharmaceuticals
CPIX
|
0.19 | $ 5.47 | 11.18 % | $ 81.3 M |  USA |
 |
Evoke Pharma
EVOK
|
-2.73 | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-6.95 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
-0.32 | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
-0.61 | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-0.16 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-0.86 | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-9.17 | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
0.27 | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
-0.01 | $ 2.63 | -4.01 % | $ 1.01 B |  Canada |
 |
Harrow Health
HROW
|
0.87 | $ 31.21 | 1.13 % | $ 1.15 B | USA |
 |
Athenex
ATNX
|
-10 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-0.42 | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
-1.44 | - | - | $ 11.5 B | USA |
 |
HEXO Corp.
HEXO
|
-0.67 | - | 2.45 % | $ 38.1 M | Canada |
 |
Eagle Pharmaceuticals
EGRX
|
6.31 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
1.3 | - | - | $ 28.9 M |  Irlanda |
 |
Organogenesis Holdings
ORGO
|
0.47 | $ 2.41 | -6.95 % | $ 305 M | USA |
 |
Bausch Health Companies
BHC
|
6.1 | $ 5.42 | -0.55 % | $ 1.98 B | Canada |
 |
Pacira BioSciences
PCRX
|
0.12 | $ 22.64 | -3.78 % | $ 1.05 B | USA |
 |
Solid Biosciences
SLDB
|
-2.03 | $ 6.92 | -9.31 % | $ 606 M | USA |
 |
Tilray
TLRY
|
-2.22 | $ 5.32 | -3.27 % | $ 3.29 B | Canada |
 |
Aurora Cannabis
ACB
|
0.09 | $ 3.32 | -0.9 % | $ 182 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-2.88 | $ 1.09 | -7.63 % | $ 1.35 M | USA |
 |
Jupiter Wellness
JUPW
|
0.16 | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
-3.52 | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
-0.37 | $ 1.07 | -1.83 % | $ 102 M | Canada |
 |
Evolus
EOLS
|
-0.39 | $ 6.5 | -1.22 % | $ 419 M | USA |
 |
Sundial Growers
SNDL
|
-71 | $ 1.43 | -2.05 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
-1.68 | $ 2.11 | 0.96 % | $ 30.9 M | USA |
 |
Emergent BioSolutions
EBS
|
-11.7 | $ 7.94 | -3.29 % | $ 407 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-4.7 | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
1.79 | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-1.13 | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
-0.45 | $ 0.77 | -6.44 % | $ 3.1 M | USA |
 |
Assertio Holdings
ASRT
|
1.32 | $ 23.32 | - | $ 149 M | USA |
 |
PetIQ
PETQ
|
2.8 | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-1.5 | $ 6.9 | -7.01 % | $ 272 M | USA |
 |
Recro Pharma
REPH
|
0.05 | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-0.2 | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-0.32 | $ 0.74 | -4.0 % | $ 37 M | USA |
 |
PLx Pharma
PLXP
|
-1.72 | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
2.92 | $ 16.48 | -4.52 % | $ 19.2 B | USA |
 |
Zomedica Corp.
ZOM
|
-0.08 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-0.82 | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-0.07 | $ 0.79 | -0.55 % | $ 28.4 M | USA |
 |
Tricida
TCDA
|
-2.97 | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-0.4 | $ 1.04 | -16.13 % | $ 4.46 M |  China |
 |
TherapeuticsMD
TXMD
|
-0.35 | $ 2.0 | 0.5 % | $ 23.1 M | USA |